No. 18-1515

Eli Lilly and Company v. Erfindergemeinschaft UroPep GbR

from the United States Court of Appeals for the Federal Circuit

See other cases from the Federal Circuit.

Docket Entries

Petition DENIED.

Reply of petitioner Eli Lilly and Company filed. (Distributed)

Brief of respondent Erfindergemeinschaft UroPep GbR in opposition filed.

Response Requested. (Due September 18, 2019)

Brief amici curiae of Sanofi, Sanofi-Aventis U.S. LLC, et al. filed. (Distributed)

Brief amici curiae of Eisai Co., Ltd., et al. filed. (Distributed)

Brief amicus curiae of High Tech Inventors Alliance filed. (Distributed)

DISTRIBUTED for Conference of 10/1/2019.

Waiver of right of respondent Erfindergemeinschaft UroPep GbR to respond filed.

Petition for a writ of certiorari filed. (Response due July 8, 2019)

Application (18A1084) granted by The Chief Justice extending the time to file until June 5, 2019.

Application (18A1084) to extend the time to file a petition for a writ of certiorari from May 6, 2019 to June 5, 2019, submitted to The Chief Justice.


Eli Lilly and Company, Petitioner, represented by Kannon K. Shanmugam

Erfindergemeinschaft UroPep GbR, Respondent, represented by Adam Karl Mortara

Amici Curiae

Eisai Inc., Amicus Curiae, represented by Stephen Blake Kinnaird

High Tech Inventors Alliance, Amicus Curiae, represented by Ginger D. Anders

Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC, f/d/b/a Aventis Pharmaceuticals Inc., and Regeneron Pharmaceuticals, Inc., Amicus Curiae, represented by George William Hicks Jr.

Last updated: July 17, 2024